Analyst Initiates Coverage of GE Healthcare, Says’ Path To Greatness Well-Paved’
Mizuho Securities initiated coverage on GE Healthcare Technologies Inc (NASDAQ: GEHC) with a Buy rating and a price target of $90. Last month, General…
‘Maker Of Promising Alzheimer’s Drug Leqembi Expects Full FDA Approval This Summer, Expanded Medicare Coverage’ – CNBC
https://www.cnbc.com/2023/02/17/maker-of-promising-alzheimer-drug-leqembi-expects-fdas-full-approval-this-summer.html
Eisai is anticipating full FDA approval of its early Alzheimer’s treatment, Leqembi, as soon
Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $310
Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $320 to $310.
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $325 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $325 price target.
Cisco, Analog Devices And 3 Stocks To Watch Heading Into Wednesday
With US futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
US Stocks Settle Mixed; Investor Optimism Improves
The CNN Money Fear and Greed index showed an improvement in the overall sentiment among US investors.
Q4 Reporting Season Pushes Past Halfway Mark: Coca-Cola, Cisco Systems, Palantir, Roku Lead Earnings This Week
The stock market pulled back in the week ended Feb. 10, dragged by some disappointing earnings and revised December inflation data.
Biogen Receives FDA Approval For Aduhelm
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its ‘Incrementally Positive’
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.